Israel Englander Aldeyra Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $1.12 Million - $1.63 Million	-344,880 Reduced 88.73%	43,825 $145,000
Q1 2024 May 15, 2024	SELL	$2.77 - $4.22 $143,161 - $218,102	-51,683 Reduced 11.74%	388,705 $1.27 Million
Q4 2023 Feb 14, 2024	SELL	$1.47 - $6.06 $81,124 - $334,433	-55,187 Reduced 11.14%	440,388 $1.55 Million
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $4.43 Million - $7.41 Million	-622,856 Reduced 55.69%	495,575 $4.16 Million
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $1.55 Million - $2.66 Million	268,343 Added 31.57%	1,118,431 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $1.03 Million - $1.44 Million	203,694 Added 31.51%	850,088 $5.92 Million
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $2.24 Million - $4.57 Million	-590,358 Reduced 47.73%	646,394 $3.45 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $1.78 Million - $3.55 Million	732,290 Added 145.16%	1,236,752 $4.94 Million
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $3.75 Million - $5.97 Million	-1,154,473 Reduced 69.59%	504,462 $2.24 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $4.4 Million - $12.1 Million	1,255,992 Added 311.7%	1,658,935 $6.64 Million
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $60,383 - $86,012	-7,605 Reduced 1.85%	402,943 $3.54 Million
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $1.39 Million - $1.98 Million	-133,275 Reduced 24.51%	410,548 $4.65 Million
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $99,464 - $219,645	-15,232 Reduced 2.72%	543,823 $6.46 Million
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $1.42 Million - $1.82 Million	224,441 Added 67.07%	559,055 $3.84 Million
Q3 2020 Nov 16, 2020	SELL	$4.0 - $7.53 $933,132 - $1.76 Million	-233,283 Reduced 41.08%	334,614 $2.48 Million
Q2 2020 Aug 14, 2020	SELL	$1.97 - $5.05 $496,302 - $1.27 Million	-251,930 Reduced 30.73%	567,897 $2.37 Million
Q1 2020 May 14, 2020	BUY	$1.62 - $6.4 $35,324 - $139,552	21,805 Added 2.73%	819,827 $2.03 Million
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $1.25 Million - $2.11 Million	264,390 Added 49.55%	798,022 $4.64 Million
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $1.29 Million - $1.79 Million	293,278 Added 122.02%	533,632 $2.81 Million
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $876,474 - $1.31 Million	-146,079 Reduced 37.8%	240,354 $1.44 Million
Q1 2019 May 14, 2019	SELL	$7.14 - $9.85 $1.94 Million - $2.67 Million	-271,543 Reduced 41.27%	386,433 $3.49 Million
Q4 2018 Feb 14, 2019	SELL	$7.26 - $13.29 $2.1 Million - $3.84 Million	-289,249 Reduced 30.54%	657,976 $5.46 Million
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $1.51 Million - $3.19 Million	222,273 Added 30.66%	947,225 $13.1 Million
Q2 2018 Aug 14, 2018	SELL	$6.95 - $9.18 $195,927 - $258,793	-28,191 Reduced 3.74%	724,952 $5.76 Million
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $245,389 - $333,429	37,464 Added 5.23%	753,143 $5.65 Million
Q4 2017 Feb 14, 2018	BUY	$5.7 - $7.75 $972,385 - $1.32 Million	170,594 Added 31.3%	715,679 $4.87 Million
Q3 2017 Nov 14, 2017	BUY	$3.9 - $10.8 $2.13 Million - $5.89 Million	545,085	545,085 $3.93 Million

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

Perceptive Advisors LLC New York, NY

9.28M
Shares

$44.4 Million
1.31% of portfolio
Knoll Capital Management, LLC Miami, FL

5.48M
Shares

$26.2 Million
14.56% of portfolio
Vanguard Group Inc Valley Forge, PA

3.76M
Shares

$18 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.62M
Shares

$17.3 Million
0.0% of portfolio
Kennedy Capital Management, Inc. St Louis, MO

1.88M
Shares

$9.01 Million
0.24% of portfolio

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account